Some patients enrolled at Providence, R.I.-based University Gastroenterology have begun to see a clinical trial of ozaminod, 10 WJAR reported Oct. 8.
The prospective phase 4, open-label study began in January 2023 and includes 500 enrolled participants across the U.S. The medication is a once-a-day pill that treats inflammation caused by inflammatory bowel disease, ulcerative colitis and Chron's.
According to the report, patients at UG have already begun to experience symptom relief after using the drug.
"I began taking the medication in August," said Matt Baker, a 34-year-old patient in the trial with ulcerative colitis. "Ultimately, for me, all I've seen is an improvement in quality of life."